A Phase I/II Trial of Trastuzumab plus Erlotinib in Metastatic HER2-Positive Breast Cancer: A Dual ErbB Targeted Approach
- 1 February 2009
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 9 (1) , 16-22
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast CancerClinical Cancer Research, 2008
- Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor NetworkClinical Cancer Research, 2007
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2006
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growthAnnals of Oncology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989